GlassScriptPhysician profile
Gregory W Horn
NPI 1659371128
$3,717.36
in general payments reported to CMS, 2019-2025
37 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $272 · 2021: $333 · 2022: $1,331 · 2023: $315 · 2024: $218 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $925.97 | 2022 | |
| Intuitive Surgical, INC. | $686.96 | 2019 | |
| Abbvie INC. | $684.97 | 2019-2025 | |
| Astellas Pharma US INC | $112.88 | 2022 | |
| Coopersurgical, INC. | $100.00 | 2020 | |
| Minerva Surgical, INC | $98.97 | 2019 | |
| Organon LLC | $95.75 | 2021-2025 | Jada System, Nexplanon |
| Baxter Healthcare | $86.48 | 2019-2020 | |
| Ethicon US, LLC | $75.59 | 2024-2025 | N/A, Vistaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $73.03 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $63.88 | 2023-2025 | |
| Therapeuticsmd, INC. | $61.20 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $52.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $46.70 | 2019-2021 | |
| Sage Therapeutics, LLC | $45.32 | 2024-2025 | Zurzuvae |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $39.08 | 2019-2021 | |
| Scynexis, INC. | $38.15 | 2022 | |
| Novo Nordisk INC | $36.99 | 2021-2023 | Wegovy |
| Sumitomo Pharma America, INC. | $35.77 | 2023 | Gemtesa |
| Roche Diagnostics Corporation | $34.71 | 2019 | |
| Mallinckrodt Enterprises LLC | $32.69 | 2019 | |
| Mylan Pharmaceuticals INC. | $28.73 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $27.66 | 2023 | Exparel |
| Exeltis, USA INC. | $23.96 | 2020 | |
| Bard Access Systems, INC. | $23.87 | 2019 | |
| Axonics, INC. | $21.98 | 2023 | Bulkamid |
| Davol INC. | $18.43 | 2024 | Arista Ah Flexitip |
| Pfizer INC. | $18.42 | 2024 | |
| Nevro Corp. | $17.90 | 2019 | |
| Daiichi Sankyo INC. | $17.62 | 2022 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Lilly USA, LLC | $14.54 | 2024 | Zepbound |
| Agile Therapeutics, INC. | $14.15 | 2021 | |
| Next Science LLC | $13.68 | 2020 | |
| Boston Scientific Corporation | $12.75 | 2019 | |
| Lupin INC. | $11.66 | 2019 | |
| Meditrina | $8.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.